New research suggests booster dose of Novovax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants researchsquare nicd_sa
By Dr. Chinta SidharthanOct 31 2022Reviewed by Aimee Molineux A recent study posted to Research Square* preprint server evaluated the neutralizing antibody titers against the severe acute respiratory syndrome coronavirus 2 Omicron variant and its sub-lineages after two and three doses of the Novovax protein nanoparticle vaccine NVX-CoV2373.
About the study In the present study, serum samples were collected from individuals in South Africa who had been administered two or three doses of the Novovax NVX-CoV2373 vaccine. The samples were collected 14 and 35 days after the second and third doses, respectively. The researchers also sampled individuals vaccinated with two doses of the adenoviral vector vaccine AD26.COV2.S or two and three doses of the mRNA vaccine BNT162b22.
Related StoriesHowever, the neutralization titers were much higher against the Omicron BA.1 and BA.4/BA.5 subvariants when measured a month after the booster dose of NVX-CoV2373 was administered. Furthermore, all plasma samples from individuals with three doses of the NVX-CoV2373 or BNT162b22 vaccine showed neutralizing action against Omicron BA.1, and BA.4/BA.5 subvariants, while only 13% to 50% of the plasma samples from individuals with two doses of AD26.COV2.S showed neutralizing activity against the Omicron subvariants.
Ireland Latest News, Ireland Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Frontiers | SARS-CoV-2 specific antibody trajectories in mothers and infants over two months following maternal infectionInfants exposed to caregivers infected with SARS-CoV-2 may have heightened infection risks relative to older children due to their more intensive care and feeding needs, and may experience more severe infection due to their less developed immune systems. However, there has been limited research on COVID-19 outcomes in exposed infants beyond the neonatal period. Between June 2020 – March 2021, we conducted interviews and collected capillary dried blood from SARS-CoV-2 infected mothers and their infants (aged 1-36 months) for up to two months following maternal infection onset (COVID+ group, 87% breastfeeding, n dyads=46 dyads). Comparative data were also collected from breastfeeding mothers with no known SARS-CoV-2 infection or exposures (breastfeeding control group, n dyads=26), and mothers who tested SARS-CoV-2 negative after experiencing symptoms or close contact exposure (COVID- group, n dyads=11, 73% breastfeeding). Dried blood samples were assayed for anti-SARS-CoV-2 S-RBD IgG and IgA positivity and anti-SARS-CoV-2 S1 + S2 IgG concentrations. Within the COVID+ group, the mean probability of seropositivity among infant samples was significantly lower than that of corresponding maternal samples (IgG 0.54 vs. 0.87; IgA 0.33 vs. 0.85), with likelihood of infant infection positively associated with the number of maternal symptoms and other household infections reported. COVID+ mothers reported a lower incidence of COVID-19 symptoms among their infants as compared to themselves and other household adults, and infants had similar PCR positivity rates as other household children. No samples returned by COVID- mothers or their infants tested antibody positive. Among the breastfeeding control group, 44% of mothers but none of their infants tested antibody positive in at least one sample. Results support previous research demonstrating minimal risks to infants following maternal COVID-19 infection, including for breastfeeding infants.
Read more »
Vimentin is an important co-receptor for SARS-CoV-2 infectionVimentin is an important co-receptor for SARS-CoV-2 infection Receptor SARSCoV2 Coronavirus Disease COVID ACE2 Vimentin iScience_CP IHU_Marseille univamu
Read more »
Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariantsResearchers at Emory University, Stanford University, and the National Institute of Allergy and Infectious Diseases evaluated whether bivalent coronavirus disease 2019 (COVID-19) boosters conferred protection against new Omicron subvariants.
Read more »
Scientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variantsScientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variants Antibody SARSCoV2 Coronavirus Disease COVID biorxivpreprint WeillCornell UWMadison scrippsresearch UChicago IcahnMountSinai seattlechildren
Read more »
Scientists identify a cryptic SARS-CoV-2 lineage in wastewaterIn a recent study posted to the medRxiv* preprint server, researchers in the United States investigated the source of an enigmatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC)-like spike (S) protein strain detected in wastewater but not in clinical samples.
Read more »